Disease relevance of Satranidazole

• In a subcutaneous Bacteroides fragilis abscess in mice, satranidazole alone produced a three log reduction in cfu of the infecting organism at 10 mg/kg, the lowest dose tested [1].
• Satranidazole: experimental evaluation of activity against anaerobic bacteria in vitro and in animal models of anaerobic infection [1].
• Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess [2].
• The incidence of nausea and metallic taste was significantly lower in the patients given satranidazole (P < .005) [2].

High impact information on Satranidazole

• The satranidazole plasma elimination half-life of 1.01 h was significantly shorter than the corresponding metronidazole half-life of 3.62 h [3].
• Comparative pharmacokinetics and amoebicidal activity of metronidazole and satranidazole in the golden hamster, Mesocricetus auratus [3].
• With a view to evaluate the possible teratogenic potential of 1-methane-sulphonyl-3-(1-methyl-5-nitro-1H-imidazole-2-yl)-2-imidazolidi none (Go 10213), groups of pregnant rats were medicated orally with: 0, 100, 300 and 600 mg/kg of the compound daily from day 6 to day 15 of gestation [4].

Associations of Satranidazole with other chemical compounds

• Blood and liver samples were collected at frequent time intervals and assayed for metronidazole and satranidazole by HPLC [3].

References